Publications

Our lab has produced seminal research on aging, epigenetics, and the development of non-invasive liquid biopsy-based biomarkers for the early detection of cancers. These papers underscore our commitment to advancing cancer research and improving patient care through innovative approaches.

Highlights include:

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Cell PMID: 22439938
Aging and DNA methylation in colorectal mucosa and cancer Cancer Research PMID: 9850084
CpG island methylator phenotype in colorectal cancer PNAS PMID: 10411935

DNA-demethylating agents have a significant effect on tumor cells. Aging affects DNA methylation in colorectal mucosa and cancer. CpG island methylator phenotype is found in colorectal cancer. These findings contribute to the understanding of cancer development and progression, paving the way for innovative approaches in cancer research and patient care.

We are conducting research on how DNA-demethylating agents impact tumor cells. We are also exploring the relationship between aging and DNA methylation in colorectal cancer. Additionally, we are identifying CpG island methylator phenotype in colorectal cancer. These methods may result in new diagnostic and therapeutic strategies.

Publications

2024

Ventral hernia repair with permanent mesh for non-Hispanic black versus white patients: access and post-operative outcomes in the era of robotic surgeryChao G, Ying L, Huang L, Ma J, Ghiassi S, Gibbs K, Nadzam G, Morton J, Duffy A, Zhou R. Ventral hernia repair with permanent mesh for non-Hispanic black versus white patients: access and post-operative outcomes in the era of robotic surgery. Surgical Endoscopy 2024, 1-8. PMID: 39433584, DOI: 10.1007/s00464-024-11252-5.
Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided RadiotherapyHicks D, Chen H, Kim J, Tressel L, Wallington D, Becht K, Johung K, Young M, Feghali K, de Jong D, Chen Z, Carlson D, Park H. Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s162-s163. DOI: 10.1016/j.ijrobp.2024.07.2188.
Evaluation of Biology-Guided Radiotherapy (BgRT) in Motion Phantom with Real Patient Breathing PatternsChen H, Han D, Draeger E, Zhong W, Lee M, Guan F, Hicks D, Park H, Johung K, Young M, Bal G, Carlson D, Chen Z. Evaluation of Biology-Guided Radiotherapy (BgRT) in Motion Phantom with Real Patient Breathing Patterns. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e107. DOI: 10.1016/j.ijrobp.2024.07.2018.
Dosimetric Analysis of Stereotactic vs. Intensity-Modulated Radiation Therapy for Pancreatic CancerOh P, Laird J, Gueble S, Johung K. Dosimetric Analysis of Stereotactic vs. Intensity-Modulated Radiation Therapy for Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e476. DOI: 10.1016/j.ijrobp.2024.07.1058.
Perioperative Modified FOLFIRINOX for Resectable Pancreatic CancerCecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.
Pancreatic Cancer Surveillance and Survival of High-Risk IndividualsBlackford A, Canto M, Dbouk M, Hruban R, Katona B, Chak A, Brand R, Syngal S, Farrell J, Kastrinos F, Stoffel E, Rustgi A, Klein A, Kamel I, Fishman E, He J, Burkhart R, Shin E, Lennon A, Goggins M. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncology 2024, 10: 1087-1096. PMID: 38959011, PMCID: PMC11223057, DOI: 10.1001/jamaoncol.2024.1930.
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.
Modern Management of Gastric Neuroendocrine NeoplasmsKunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.
Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis.Magahis P, Chhoda A, Berzin T, Farrell J, Wright D, Rizvi A, Hanscom M, Carr-Locke D, Sampath K, Sharaiha R, Mahadev S. Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2024 PMID: 38976379, DOI: 10.14309/ajg.0000000000002942.
Weight Nadir and Long-Term Weight Outcomes After Laparoscopic Sleeve Gastrectomy in a Diverse Cohort of Adolescents and Young AdultsHornick M, Chao G, Ying L, Nadzam G, Duffy A, Ghiassi S, Graetz E, Gibbs K, Morton J. Weight Nadir and Long-Term Weight Outcomes After Laparoscopic Sleeve Gastrectomy in a Diverse Cohort of Adolescents and Young Adults. Obesity Surgery 2024, 34: 2965-2973. PMID: 38935262, DOI: 10.1007/s11695-024-07374-3.
Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision OncologyTan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B, He L, Sharma A, Ahuja N. Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology. Current Issues In Molecular Biology 2024, 46: 6533-6565. PMID: 39057032, PMCID: PMC11276574, DOI: 10.3390/cimb46070390.
Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic ConsultationSu D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.
American society for metabolic and bariatric surgery: intra-operative care pathway for minimally invasive Roux-en-Y gastric bypassLin H, Baker J, Meister K, Lak K, Martin Del Campo S, Smith A, Needleman B, Nadzam G, Ying L, Varban O, Reyes A, Breckenbridge J, Tabone L, Gentles C, Echeverri C, Jones S, Gould J, Vosburg W, Jones D, Edwards M, Nimeri A, Kindel T, Petrick A. American society for metabolic and bariatric surgery: intra-operative care pathway for minimally invasive Roux-en-Y gastric bypass. Surgery For Obesity And Related Diseases 2024, 20: 895-909. PMID: 39097472, DOI: 10.1016/j.soard.2024.06.002.
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome AnalysisJohnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Gurski L, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 38862008, DOI: 10.6004/jnccn.2024.0029.
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancerVerma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.
Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision OncologyTan, Wan Ying, Snigdha Nagabhyrava, Olivia Ang-Olson, Paromita Das, Luisa Ladel, Bethsebie Sailo, Linda He, Anup Sharma, and Nita Ahuja. 2024. "Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology" Current Issues in Molecular Biology 46, no. 7: 6533-6565. https://doi.org/10.3390/cimb46070390
Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resectionYing L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.
Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysisSilva-Santisteban A, Hernandez Woodbine M, Noriega M, Rabinowitz L, Grimshaw A, Farrell J, Chhoda A, Sawhney M. Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2024, 100: 1-16.e20. PMID: 38432492, DOI: 10.1016/j.gie.2024.02.014.
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patientsLee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.
Abstract A072: Keratin 17-signature for stratification of chemotherapy in pancreatic adenocarcinomaChowdhury S, Yugawa D, Tseng R, Mejia M, Lacy J, Patel T, Escobar-Hoyos L, Shroyer K, Cai G, Robert M, Cecchini M, Kunstman J, Farrell J, Johung K. Abstract A072: Keratin 17-signature for stratification of chemotherapy in pancreatic adenocarcinoma. Cancer Research 2024, 84: a072-a072. DOI: 10.1158/1538-7445.panca2023-a072.
Outcomes of SADI and OAGB Compared to RYGB from the Metabolic and Bariatric Surgery Quality Improvement Program: The North American ExperienceChao G, Canner J, Hamid S, Ying L, Ghiassi S, Schwartz J, Gibbs K. Outcomes of SADI and OAGB Compared to RYGB from the Metabolic and Bariatric Surgery Quality Improvement Program: The North American Experience. Obesity Surgery 2024, 34: 337-346. PMID: 38170422, DOI: 10.1007/s11695-023-07019-x.

2023

Clinical predictive value of renalase in post-ERCP pancreatitisMuniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Clinical predictive value of renalase in post-ERCP pancreatitis. Gastrointestinal Endoscopy 2023, 99: 822-825.e1. PMID: 38103747, DOI: 10.1016/j.gie.2023.12.020.
The Degree of Preoperative Hypoalbuminemia Is Associated with Risk of Postoperative Complications in Metabolic and Bariatric Surgery PatientsYing L, Chao G, Canner J, Graetz E, Ghiassi S, Schwartz J, Zolfaghari E, Schneider E, Gibbs K. The Degree of Preoperative Hypoalbuminemia Is Associated with Risk of Postoperative Complications in Metabolic and Bariatric Surgery Patients. Obesity Surgery 2023, 34: 51-70. PMID: 37994997, DOI: 10.1007/s11695-023-06944-1.
Role of colectomy in the management of appendiceal tumors: a retrospective cohort studyMarks V, Kerekes D, Butensky S, Ahuja N, Johnson C, Turaga K, Khan S. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. BMC Gastroenterology 2023, 23: 398. PMID: 37978348, PMCID: PMC10655451, DOI: 10.1186/s12876-023-03019-4.
Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19Peters N, O'Connor R, Bhattacharya B, Kunstman J. Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19. Heliyon 2023, 9: e22043. PMID: 38027854, PMCID: PMC10658381, DOI: 10.1016/j.heliyon.2023.e22043.
S149 Can Pancreatic Cyst Detection Ratio Function as a Quality Indicator for EUS-Based Pancreatic Cancer Screening? A Systematic Review and Meta-AnalysisChhoda A, Woodbine M, Silva-Santisteban A, Grimshaw A, Gunderson C, Farrell J, Sawhney M. S149 Can Pancreatic Cyst Detection Ratio Function as a Quality Indicator for EUS-Based Pancreatic Cancer Screening? A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2023, 118: s115-s116. DOI: 10.14309/01.ajg.0000950236.60039.42.
S119 Disparities in Race, Ethnicity, Sex, and Age Inclusion in Pancreatic Cancer Screening Studies: A Systematic Review and Meta-AnalysisSilva-Santisteban A, Chhoda A, Woodbine M, Rabinowitz L, Grimshaw A, Farrell J, Sawhney M. S119 Disparities in Race, Ethnicity, Sex, and Age Inclusion in Pancreatic Cancer Screening Studies: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2023, 118: s95-s99. DOI: 10.14309/01.ajg.0000950116.35207.91.
The Promise of Epigenetics Research in the Treatment of Appendiceal NeoplasmsLadel L, Tan W, Jeyakanthan T, Sailo B, Sharma A, Ahuja N. The Promise of Epigenetics Research in the Treatment of Appendiceal Neoplasms. Cells 2023, 12: 1962. PMID: 37566041, PMCID: PMC10417136, DOI: 10.3390/cells12151962.
Impact of COVID-19 on the gastrointestinal surgical oncology patient populationBakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.
Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United StatesKerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerCecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.
Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancerPeters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
Sa1408 PREDICTIVE VALUE OF RENALASE IN POST-ERCP PANCREATITISMuniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Sa1408 PREDICTIVE VALUE OF RENALASE IN POST-ERCP PANCREATITIS. Gastroenterology 2023, 164: s-384-s-385. DOI: 10.1016/s0016-5085(23)01894-2.
76 ROLE OF COLECTOMY FOR APPENDICEAL TUMORSMarks V, Kerekes D, Ahuja N, Turaga K, Khan S. 76 ROLE OF COLECTOMY FOR APPENDICEAL TUMORS. Gastroenterology 2023, 164: s-1442. DOI: 10.1016/s0016-5085(23)04363-9.
A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancerBaretti M, Murphy A, Zahurak M, Gianino N, Parkinson R, Walker R, Lopez-Vidal T, Zheng L, Rosner G, Ahuja N, Kurt S, Azad N. A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics 2023, 15: 74. PMID: 37120591, PMCID: PMC10149019, DOI: 10.1186/s13148-023-01485-x.
Early Detection of Cancers in the Era of Precision OncologyTan W, Sharma A, Das P, Ahuja N. Early Detection of Cancers in the Era of Precision Oncology. Current Opinion In Oncology 2023, 35: 115-124. PMID: 36721896, DOI: 10.1097/cco.0000000000000931.
Early Detection of Cancers in the Era of Precision OncologyWan Ying Tan, Anup Sharma, Paromita Das, Nita Ahuja (2023). Early Detection of Cancers in the Era of Precision Oncology. Curr Opin Oncol. 1;35(2):115-124. DOI: 10.1097/CCO.0000000000000931. PMID: 36721896 (Review article)
Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasmsChhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.
Comparison of Male and Female Surgeons’ Experiences With Gender Across 5 Qualitative/Quantitative DomainsZogg C, Kandi L, Thomas H, Siki M, Choi A, Guetter C, Smith C, Maduakolam E, Kondle S, Stein S, Shaughnessy E, Ahuja N. Comparison of Male and Female Surgeons’ Experiences With Gender Across 5 Qualitative/Quantitative Domains. JAMA Surgery 2023, 158: e226431. PMID: 36477515, PMCID: PMC9857060, DOI: 10.1001/jamasurg.2022.6431.
Use of distinct molecular signatures of appendiceal cancer subtypes to assess biomarker development.Tan W, Tian M, Ruzgar N, Hengartner A, Sailo B, Ang-Olson O, Ubas A, John N, Yaghoobi V, Tang H, Sharma A, Nalbantoglu I, Ahuja N. Use of distinct molecular signatures of appendiceal cancer subtypes to assess biomarker development. Journal Of Clinical Oncology 2023, 41: 189-189. DOI: 10.1200/jco.2023.41.4_suppl.189.
Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance.Klute K, Lucas A, Brand R, Everett J, Farrell J, Hawthorne K, Kaul V, Kupfer S, Paiella S, Simeone D, Sussman D, Zogopoulos G, Kastrinos F, Katona B, Consortium A. Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance. Journal Of Clinical Oncology 2023, 41: 687-687. DOI: 10.1200/jco.2023.41.4_suppl.687.
Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.Haimi I, Zogopoulos G, Dettwyler S, Everett J, Bi Y, Brand R, Chung D, Farrell J, Grossberg A, Kastrinos F, Katona B, Klute K, Kupfer S, Lucas A, Paiella S, Parmigiani G, Permuth J, Sears R, Sussman D, Simeone D, Consortium P. Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer. Journal Of Clinical Oncology 2023, 41: 689-689. DOI: 10.1200/jco.2023.41.4_suppl.689.
Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?Farrell J, Robert M, Lacy J. Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity? Clinical Gastroenterology And Hepatology 2023, 21: 2740-2742. PMID: 36640803, DOI: 10.1016/j.cgh.2022.12.033.

2022

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceHeumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.
Utilization and Outcomes of Radiation in Stage IV Esophageal CancerZhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.
Dosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung MetastasesLaird J, Mokhtech M, Johung K, Park H, Jethwa K. Dosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e431-e432. DOI: 10.1016/j.ijrobp.2022.07.1640.
Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic CancerOh P, Laird J, Johung K. Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e197. DOI: 10.1016/j.ijrobp.2022.07.1113.
The role of preoperative toxicology screening in patients undergoing bariatric surgeryChao G, Ying L, Chan S, Alturki N, Aravind P, Thaqi M, Mahmoud A, Morton J. The role of preoperative toxicology screening in patients undergoing bariatric surgery. Surgery For Obesity And Related Diseases 2022, 19: 187-193. PMID: 36443215, DOI: 10.1016/j.soard.2022.10.021.
Reply to S. RaoofDbouk M, Katona B, Brand R, Chak A, Syngal S, Farrell J, Kastrinos F, Stoffel E, Canto M, Goggins M. Reply to S. Raoof. Journal Of Clinical Oncology 2022, 41: 1147-1149. PMID: 36315911, PMCID: PMC9928686, DOI: 10.1200/jco.22.01915.
Bile acid distributions, sex-specificity, and prognosis in colorectal cancerCai Y, Shen X, Lu L, Yan H, Huang H, Gaule P, Muca E, Theriot CM, Rattray Z, Rattray NJW, Lu J, Ahuja N, Zhang Y, Paty PB, Khan SA, Johnson CH. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. Biology Of Sex Differences 2022, 13: 61. PMID: 36274154, PMCID: PMC9590160, DOI: 10.1186/s13293-022-00473-9.
Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas CancerMokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
How Male and Female Surgeons’ Experiences with Gender in Surgery Compare: National Concurrent Mixed-Methods Survey of Fellows of the American College of SurgeonsZogg C, Kandi L, Thomas H, Siki M, Ahuja N. How Male and Female Surgeons’ Experiences with Gender in Surgery Compare: National Concurrent Mixed-Methods Survey of Fellows of the American College of Surgeons. Journal Of The American College Of Surgeons 2022, 235: s221-s222. DOI: 10.1097/01.xcs.0000894740.81658.e5.
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 1139-1167. PMID: 36240850, DOI: 10.6004/jnccn.2022.0051.
S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver DiseaseIlagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.
Analyzing Resident Perceptions of Current Radiation Oncology Evaluation MethodsManjunath R, Rajeev-Kumar G, Tendulkar R, Corbin K, Johung K, Evans S, Shinohara E, Buckstein M, Pinnix C, Harkenrider M, Golden D, Hasan Y. Analyzing Resident Perceptions of Current Radiation Oncology Evaluation Methods. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e6. DOI: 10.1016/j.ijrobp.2022.06.007.
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and SurvivalDbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, Kastrinos F, Stoffel EM, Blackford AL, Rustgi AK, Dudley B, Lee LS, Chhoda A, Kwon R, Ginsberg GG, Klein AP, Kamel I, Hruban RH, He J, Shin EJ, Lennon AM, Canto MI, Goggins M. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal Of Clinical Oncology 2022, 40: 3257-3266. PMID: 35704792, PMCID: PMC9553376, DOI: 10.1200/jco.22.00298.
Access to telehealth services for colorectal cancer patients in the United States during the COVID-19 pandemicMarks VA, Hsiang WR, Umer W, Haleem A, Kim D, Kunstman JW, Leapman MS, Schuster KM. Access to telehealth services for colorectal cancer patients in the United States during the COVID-19 pandemic. The American Journal Of Surgery 2022, 224: 1267-1273. PMID: 35701240, PMCID: PMC9176198, DOI: 10.1016/j.amjsurg.2022.06.005.
SURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVALBlackford A, Canto M, Dbouk M, Kerdsirichairat T, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Stoffel E, Syngal S, Klein A, Hruban R, Goggins M. SURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVAL. Gastrointestinal Endoscopy 2022, 95: ab544-ab545. DOI: 10.1016/j.gie.2022.04.1334.
The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D, Consortium T. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.
Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-AnalysisChhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.
Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMSChhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.
Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSISSingh S, Chhoda A, Vodusek Z, Khatri R, Gunderson C, McCarty T, Sharma P, Grimshaw A, Kunstman J, Sharma A, Ahuja N, Gonda T, Farrell J. Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2022, 162: s-907. DOI: 10.1016/s0016-5085(22)62148-6.
1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASEKhatri R, Chhoda A, Sharma A, Farrell J, Ahuja N, Ehrlich A, Friedenberg F. 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE. Gastroenterology 2022, 162: s-270-s-271. DOI: 10.1016/s0016-5085(22)60641-3.
1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORTDbouk M, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Kwon R, Stoffel E, Syngal S, Shin E, Canto M, Goggins M. 1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORT. Gastroenterology 2022, 162: s-242-s-243. DOI: 10.1016/s0016-5085(22)60577-8.
A risk-adjusted analysis of drain use in pancreaticoduodenectomy: Some is good, but more may not be better.Brubaker LS, Casciani F, Fisher WE, Wood AL, Cagigas MN, Trudeau MT, Parikh VJ, Baugh KA, Asbun HJ, Ball CG, Behrman SW, Berger AC, Bloomston MP, Callery MP, Christein JD, Fernandez-Del Castillo C, Dillhoff ME, Dixon E, House MG, Hughes SJ, Kent TS, Kunstman JW, Wolfgang CL, Zureikat AH, Vollmer CM, Van Buren G. A risk-adjusted analysis of drain use in pancreaticoduodenectomy: Some is good, but more may not be better. Surgery 2022, 171: 1058-1066. PMID: 34433515, DOI: 10.1016/j.surg.2021.07.026.
Defer Dissection: Radiation Therapy and Systemic TherapyMokhtech M, Johung KL. Defer Dissection: Radiation Therapy and Systemic Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 1074-1075. PMID: 35286879, DOI: 10.1016/j.ijrobp.2021.12.169.
Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With SurgeryBakkila BF, Kerekes D, Nunez-Smith M, Billingsley KG, Ahuja N, Wang K, Oladele C, Johnson CH, Khan SA. Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery. JAMA Network Open 2022, 5: e225664. PMID: 35377425, PMCID: PMC8980937, DOI: 10.1001/jamanetworkopen.2022.5664.
Correction to: Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay JY, Strauss D, Rutkowski P, Ahuja N, Gonzalez R, Grignani G, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty VG, Canter RJ, Mullen JT, Pennacchioli E, van Houdt W, Swallow CJ, Schrage Y, Cardona K, Fiore M, Gronchi A, Bagaria SP. Correction to: Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals Of Surgical Oncology 2022, 29: 4390-4390. PMID: 35307808, DOI: 10.1245/s10434-022-11600-6.
Correction to: Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG).Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Rutkowski P, Blay JY, Strauss D, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Swallow CJ, Bagaria SP, Canter RJ, Mullen JT, Schrage Y, Pennacchioli E, van Houdt W, Cardona K, Fiore M, Gronchi A, Lahat G. Correction to: Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). Annals Of Surgical Oncology 2022 PMID: 35307809, DOI: 10.1245/s10434-022-11602-4.
Correction: ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Nessim C, Raut C, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay J, Strauss D, Rutkowski P, Ahuja N, Gonzalez R, Grignani G, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty V, Canter R, Mullen J, Pennacchioli E, van Houdt W, Swallow C, Schrage Y, Cardona K, Fiore M, Gronchi A, Bagaria S. Correction: ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals Of Surgical Oncology 2022, 29: 4391-4391. DOI: 10.1245/s10434-022-11601-5.
Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group.Bagaria SP, Swallow C, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, Grignani G, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock R, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel MR, Li Z, Fiore M, Gronchi A. Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals Of Surgical Oncology 2022 PMID: 35301612, DOI: 10.1245/s10434-022-11599-w.
Less Is More: Lower Doses for Intermediate-Term Oropharyngeal ControlJohung KL, Park HS. Less Is More: Lower Doses for Intermediate-Term Oropharyngeal Control. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 585. PMID: 35101192, DOI: 10.1016/j.ijrobp.2021.07.1707.
International external validation of a stratification tool to identify branch‐duct intraductal papillary mucinous neoplasms at lowest risk of progressionOverbeek KA, van Leeuwen N, Tacelli M, Anwar MS, Yousaf MN, Chhoda A, Arcidiacono PG, Gonda TA, Wallace MB, Capurso G, Farrell JJ, Cahen DL, Bruno MJ. International external validation of a stratification tool to identify branch‐duct intraductal papillary mucinous neoplasms at lowest risk of progression. United European Gastroenterology Journal 2022, 10: 169-178. PMID: 35199484, PMCID: PMC8911544, DOI: 10.1002/ueg2.12207.
Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort StudyShen X, Cai Y, Lu L, Huang H, Yan H, Paty PB, Muca E, Ahuja N, Zhang Y, Johnson CH, Khan SA. Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study. Metabolites 2022, 12: 164. PMID: 35208238, PMCID: PMC8875032, DOI: 10.3390/metabo12020164.
Abstract PO-155: Racial heterogeneity in the molecular landscape of pancreatic adenocarcinoma: A call for actionLarson H, Chhoda A, Hengartner A, Hasan N, Ruzgar N, Yalamanchi S, Kunstman J, Farrell J, Sharma A, Ahuja N. Abstract PO-155: Racial heterogeneity in the molecular landscape of pancreatic adenocarcinoma: A call for action. Cancer Epidemiology Biomarkers & Prevention 2022, 31: po-155-po-155. DOI: 10.1158/1538-7755.disp21-po-155.

2021

GCM2 Variants in Familial and Multiglandular Primary HyperparathyroidismVincze S, Peters NV, Kuo CL, Brown TC, Korah R, Murtha TD, Bellizzi J, Riccardi A, Parham K, Carling T, Costa-Guda J, Arnold A. GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e2021-e2026. PMID: 34967908, DOI: 10.1210/clinem/dgab929.
Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control studyYaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O’Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study. Breast Cancer Research 2021, 23: 113. PMID: 34906209, PMCID: PMC8670126, DOI: 10.1186/s13058-021-01493-w.
Colorectal cancer survivorship care plans: Variations in documentation and posttreatment surveillance recommendationsChodoff A, Smith KC, Shukla A, Blackford AL, Ahuja N, Johnston FM, Peairs KS, Ngaiza JR, Warczynski T, Nettles B, Stotsky‐Himelfarb E, Murphy AG, Mayonado N, DeSanto J, Snyder CF, Choi Y. Colorectal cancer survivorship care plans: Variations in documentation and posttreatment surveillance recommendations. Journal Of Surgical Oncology 2021, 125: 678-691. PMID: 34894361, DOI: 10.1002/jso.26767.
Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital SystemPatel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, PMCID: PMC8748034, DOI: 10.21037/jgo-21-202.
Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-AnalysisChhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2021, 162: 786-798. PMID: 34813861, DOI: 10.1053/j.gastro.2021.11.021.
Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer FacilitiesMarks VA, Hsiang WR, Umer W, Haleem A, Leapman MS, Kunstman JW, Schuster KM. Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities. Annals Of Surgical Oncology 2021, 29: 1518-1522. PMID: 34762215, DOI: 10.1245/s10434-021-11053-3.
Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection ConsortiumGonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, Saunders M, Siddiqui UD, Brand R, Simeone DM, Consortium P, Amundadottir L, Beyer G, Bi Y, Brentnall T, Carpizo D, Carrato A, Chandarana H, Chun J, Chung D, Dudley B, Earl J, Everett J, Fava M, Gaddam S, Gallinger S, Golan T, Graff J, Greenhalf W, Grossberg A, Hart P, Holter S, Huang C, Idos G, Kanth P, Kastrinos F, Katona B, Kaul V, Klute K, Kupfer S, Liau J, Lin J, Lindberg J, Lowy A, Lucas A, Mayerle J, Merchant N, Paiella S, Permuth J, Schrader I, Sears R, Siveke J, Sussman D, Zogopoulos G. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointestinal Endoscopy 2021, 95: 723-732.e7. PMID: 34736932, DOI: 10.1016/j.gie.2021.10.025.
Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology ProgramsRajeev-Kumar G, Manjunath R, Harkenrider M, Das P, Tendulkar R, Corbin K, Jagsi R, Marwaha G, Johung K, Evans S, Jawad M, Shinohara E, Komarnicky L, Yeung A, Buckstein M, Golden D, Hasan Y. Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology Programs. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e191. DOI: 10.1016/j.ijrobp.2021.07.697.
SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic CancerMorris L, Viehman J, Baclay J, Chang D, Kerans S, Molitoris J, Regine W, Johung K, Jethwa K, Neibart S, Jabbour S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e61. DOI: 10.1016/j.ijrobp.2021.07.408.
Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group.Bagaria SP, Swallow C, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, Grignani G, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock R, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel MR, Li Z, Fiore M, Gronchi A. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals Of Surgical Oncology 2021, 28: 6882-6889. PMID: 33740198, DOI: 10.1245/s10434-021-09739-9.
The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis.Casciani F, Trudeau MT, Asbun HJ, Ball CG, Bassi C, Behrman SW, Berger AC, Bloomston MP, Callery MP, Christein JD, Falconi M, Fernandez-Del Castillo C, Dillhoff ME, Dickson EJ, Dixon E, Fisher WE, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, Partelli S, Wolfgang CL, Zureikat AH, Vollmer CM. The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery 2021, 170: 1195-1204. PMID: 33931208, DOI: 10.1016/j.surg.2021.03.044.
Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic CancerYing L, Sharma A, Chhoda A, Ruzgar N, Hasan N, Kwak R, Wolfgang CL, Wang TH, Kunstman JW, Salem RR, Wood LD, Iacobuzio-Donahue C, Schneider EB, Farrell JJ, Ahuja N. Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Pancreas 2021, 50: 1267-1273. PMID: 34860810, DOI: 10.1097/mpa.0000000000001919.
S1030 Prevalence and Predictors of Musculoskeletal Disorders Amongst Nurses and Technicians Assisting in ERCPMbachi C, Jamidar P, Muniraj T, Farrell J, , Campbell E, Aslanian H. S1030 Prevalence and Predictors of Musculoskeletal Disorders Amongst Nurses and Technicians Assisting in ERCP. The American Journal Of Gastroenterology 2021, 116: s489-s489. DOI: 10.14309/01.ajg.0000777652.16974.b4.
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinomaGao Y, Wang M, Guo X, Hu J, Chen TM, Finn S, Lacy J, Kunstman JW, H. C, Bellin MD, Robert ME, Desir GV, Gorelick FS. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLOS ONE 2021, 16: e0250539. PMID: 34587190, PMCID: PMC8480607, DOI: 10.1371/journal.pone.0250539.
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—LetterKatona BW, Brand RE, Canto MI, Chak A, Farrell JJ, Kastrinos F, Rustgi AK, Stoffel EM, Syngal S, Goggins M. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter. Cancer Prevention Research 2021, 14: 973-974. PMID: 34607877, PMCID: PMC8500478, DOI: 10.1158/1940-6207.capr-21-0233.
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceHeumann T, Baretti M, Sugar E, Durhman J, Liden S, Miles T, Lopez-Vidal T, Leatherman J, Sharma A, Ahuja N, Weekes C, O'Dwyer P, Monga D, Binder K, Azad N. 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals Of Oncology 2021, 32: s1087-s1088. DOI: 10.1016/j.annonc.2021.08.797.
Analysis of Resident and Faculty Assessment Methods Used by United States Radiation Oncology Residency ProgramsRajeev-Kumar G, Manjunath R, Tendulkar R, Corbin K, Jagsi R, Marwaha G, Johung K, Evans S, Jawad M, Komarnicky-Kocher L, Shinohara E, Yeung A, Buckstein M, Das P, Harkenrider M, Golden D, Hasan Y. Analysis of Resident and Faculty Assessment Methods Used by United States Radiation Oncology Residency Programs. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e6-e7. DOI: 10.1016/j.ijrobp.2021.05.146.
2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancerKang X, Qin J, Zhang R, Wang Z, Zheng Q, Li Y, Xu J, Huang J, Wang X, Hui Z, Xue L, Mao Y, Li Y, He J, Chen C, Chen H, Chen K, Chen L, Fu M, Fu J, Geng Q, Gong T, Guo S, Han Y, He Y, Hu J, Jiang H, Jiang J, Jiang Y, Kang M, Ma J, Ma S, Liao Y, Li H, Li S, Li Z, Liu S, Liu Y, Qiao G, Tan L, Tian H, Zhao G, Zhao J, Zheng S, Zhou Y, Nilsson M, Schlottmann F, Rosati R, Stefano C, Chiu P, Newman N, Hirahara N, Kim D, Mehta R, Johung K, Cecchini M, Lloyd S, Meredith K. 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer. Annals Of Esophagus 2021, 4: 33-33. DOI: 10.21037/aoe-21-64.
Performing Bariatric Surgery on Previously COVID+ Patients Is Safe and EffectiveCheung MS, Ying L, Duffy AJ, Ghiassi S, Nadzam G, Roberts KE, Morton JM. Performing Bariatric Surgery on Previously COVID+ Patients Is Safe and Effective. Obesity Surgery 2021, 31: 5082-5084. PMID: 34453312, PMCID: PMC8396140, DOI: 10.1007/s11695-021-05659-5.
Immunotherapy Treatment for Triple Negative Breast CancerBerger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 2021, 14: 763. PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.
Epigenetic signatures differentiate uterine and soft tissue leiomyosarcomaHasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, Ahuja N. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. Oncotarget 2021, 12: 1566-1579. PMID: 34381562, PMCID: PMC8351604, DOI: 10.18632/oncotarget.28032.
Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trialSmith KC, White S, DeSanto J, Hannum S, Mayonado N, Ahuja N, Bowie J, Cowall D, Mischtschuk J, Peairs K, Thorner E, Tran P, Wolff A, Snyder C. Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. Journal Of Cancer Survivorship 2021, 16: 791-800. PMID: 34296383, DOI: 10.1007/s11764-021-01073-z.

Download Full List